Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa

PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005163. doi: 10.1371/journal.pntd.0005163. eCollection 2017 Jan.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Africa / epidemiology
  • Albendazole / administration & dosage
  • Albendazole / therapeutic use*
  • Anthelmintics / administration & dosage
  • Anthelmintics / therapeutic use*
  • Diethylcarbamazine / administration & dosage
  • Diethylcarbamazine / therapeutic use*
  • Drug Therapy, Combination
  • Elephantiasis, Filarial / drug therapy*
  • Elephantiasis, Filarial / epidemiology
  • Elephantiasis, Filarial / prevention & control
  • Humans
  • Ivermectin / administration & dosage
  • Ivermectin / therapeutic use*
  • Onchocerciasis / drug therapy*
  • Onchocerciasis / epidemiology
  • Onchocerciasis / prevention & control

Substances

  • Anthelmintics
  • Ivermectin
  • Albendazole
  • Diethylcarbamazine

Grant support

This work was supported by a grant of the Bill & Melinda Gates Foundation (GH5342). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The funders advised on the design of the study, had no role in data collection and analysis, had no role in decision to publish, and contributed in the writing of the manuscript.